Lastly, histopathologic evaluation of tibia bone marrow from mice infused with CAR.CD19-T cells and treated with emapalumab showed a significant reduction in phagocytic cells or mitoses (Supplementary Fig. 7, bottom panels) compared to mice not given emapalumab which develop severe CRS. The gene discussed is CD19; the disease is congenital rubella syndrome.